MIF functional polymorphisms are associated with acute GVHD progression and steroid-refractoriness
IntroductionApproximately 50% of allogeneic hematopoietic stem cell transplantation (HSCT) Q6 recipients develop graft versus host disease (GVHD). Glucocorticoids (GC) are the first line of treatment for both acute and chronic GVHD. Failure to respond to GC [steroid-refractory (SR)] encompasses a ve...
Saved in:
| Main Authors: | Aviran Aharon, Batia Avni, Daniel Louzoun, Shlomo Elias, Polina Stepensky, Ron Ram, Tsila Zuckerman, Roberto Meza-Romero, Arthur A. Vandenbark, Sigal Grisariu, Gil Benedek |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1504976/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Low dose ATG-Fresenius for GVHD prophylaxis: a comparative study with ATG-Thymoglobulin
by: Itai Falicovich, et al.
Published: (2025-01-01) -
The Microbiome, Inflammation, and GVHD Axis: The Balance Between the “Gut” and the Bad
by: Paula Pinzon-Leal, et al.
Published: (2025-03-01) -
Advancements in graft-versus-host disease prevention in hematopoietic stem cell transplantation
by: Soumyajit Das, et al.
Published: (2025-01-01) -
Diagnostic and prognostic role of elafin in skin acute graft versus host disease: a systematic review
by: Abhinav Bhattarai, et al.
Published: (2024-12-01) -
Donor‐derived M2 macrophages attenuate GVHD after allogeneic hematopoietic stem cell transplantation
by: Ryo Hanaki, et al.
Published: (2021-12-01)